Compare Amylx Pharmaceuticals Inc (AMLX) vs Funko Inc (FNKO) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

FNKO trades at $5.58, up 3.91% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with revenue declining to $908M in 2025 and a net loss of $67M, though recent quarters beat EPS estimates. Analyst consensus is divided with 42.9% buy ratings, while positive news includes new product launches and Q1 2026 revenue growth to $200.9M. Cash flow improved to a net positive $7.5M in 2025 from negative trends in prior years.

Outlook remains cautious due to persistent losses and high debt, but recent execution improvements and product innovation offer potential upside. Key risks include margin pressure and competitive threats in the collectibles market. Investors should weigh the bullish analyst sentiment against fundamental challenges before considering a position.